Summary
Ovulation-induction agents are commonly used in the treatment of infertility in patients with or without ovulatory disturbances. These agents include Clomifene, bromocriptine, gonadotrophin preparations and gonadotrophin-releasing hormone (GnRH) and its analogues. Each agent is associated with its own specific adverse effects. Although many of these adverse effects are benign and self-limited, some, in particular those effects associated with gonadotrophins, may be life-threatening.
Commonly noted adverse effects encountered with the use of pharmacological agents to treat infertility include the following. Clomifene has been associated with hot flushes, multiple gestation, visual disturbances, cervical mucus abnormalities and luteal phase deficiency. Similarly, most of the adverse symptoms associated with bromocriptine are short-lived, such as nausea and postural hypotension. On the other hand, gonadotrophin therapy, even when used appropriately, may lead to the ovarian hyperstimulation syndrome (which is occasionally life-threatening) and a high incidence of multiple gestation. Pulsatile GnRH therapy maybe accompanied by similar adverse effects to those of gonadotrophins, but with a far lower incidence.
With regards to the long term safety of these medications, the relationship between fertility drugs and epithelial ovarian cancer is controversial, and causality has yet to be proven. Indeed, a working knowledge of the many adverse effects associated with these medications is essential to any physician prescribing ovulation induction agents, in order to ensure maximum patient safety, compliance and understanding.
Similar content being viewed by others
References
Wilcox LS, Mosher WD. Use of infertility services in the United States. Obstet Gynecol 1993; 82: 122–7
World Helath Organization. Infections, pregnancies and infertility: perspectives on prevention. Fertil Steril 1987; 47: 964–8
Jones HW, Toner JP. The infertile couple. N Engl J Med 1993; 329: 1710–5
Greenblatt RB, Barfield WE, Jungck EC, et al. Induction of ovulation with MRL/41. JAMA 1961; 178: 101
Palopoli FP, Feil VJ, Allen RE, et al. Substituted aminoalkoxytriarylhado-ethylenes. J Med Chem 1967; 10: 84
Clark JH, Markaverian BM. The agonistic-antagonistic properties of clomiphene: a review. Pharmacol Ther 1982; 15: 467
Adashi EY. Clomphene citrate: mechanism(s) and site(s) of action. A hypothesis revisited. Fertil Steril 1984; 42: 331–44
Goldfarb AF, Crawford R. Polycystic ovarian disease, clomiphene and multiple pregnancies. Obstet Gynecol 1969; 34: 307
Yen SSC, Vela P, Ryan KJ. Effect of clomiphene citrate in polycystic ovary syndrome: relationship between serum gonadotropin and corpus luteum function. J Clin Endocrinol Metab 1970; 31: 7
Lunenfeld B, Insler V. Classification of ammenorrhoeic states and their treatment by ovulation induction. Clin Endocrinol 1974; 3: 233
McClamrock HD, Katz E, Adashi EY. Clomiphene citrate: a 1990 update. Infertil Reprod Med Clin North Am 1990; 1: 37–58
Echt CR, Romberger FT, Goodman JA. Clomiphene citrate in the treatment of luteal phase defects. Fertil Steril 1969; 20: 564
Quagliarello J, Weiss G. Clomiphene citrate in the management of infertility associated with shortened luteal phases. Fertil Steril 1979; 31: 373
diZerega GS, Hodgen GD. Luteal phase dysfunction in infertility: a sequel to aberrant folliculogenesis. Fertil Steril 1981; 35: 489
McClamrock HD, Adashi EY. Ovulation induction part I: appropriate use of clomiphene citrate. Female Patient 1988; 1: 92–106
Klay LG. Clomiphene regulated ovulation for donor insemination. Fertil Steril; 1976; 27: 383
Dickey RP, Olar TT. Clomiphene citrate-induced intrauterine insemination cycles. Assisted Reprod Rev 1993; 3: 108–20
Trounson AO, Leeton JF, Wood C, et al. Pregnancies in human by fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science 1981; 212: 681
Gambreil RD, Greenblatt RB, Mahesh VB. Serum gonadotropins in a variety of ovulatory women treated with clomiphene citrate. Int J Gynecol Obstet 1973; 11: 90
Littman BA, Hodgen GD. A comprehensive dose-response study of clomiphene citrate for enhancement of the primate ovarian menstrual cycle. Fertil Steril 1985; 43: 463
Adashi EY. Clomiphene citrate-initiated ovulation: a clinical update. Semin Reprod Endocrinol 1986; 4: 255–76
Jones GS, DeMoraes-Reuhsen M. Induction of ovulation with human gonadotropins with clomiphene. Fertil Steril 1965; 16: 461
Kistner RW. The infertile women. J Nurs 1973; 73: 1937
Asch RH, Greenblatt RB. Update on the safety and efficacy of clomiphene citrate as a therapeutic agent. J Reprod Med 1976; 17: 175
Atlay RD, Pennington GW. The use of clomiphene citrate and pituitary gonadotropin in successive pregnancies: the Sheffield quadruplets. Am J Obstet Gynecol 1971; 109: 402
Aiken RA. An account of the ‘Birmingham sextuplets’. J Obstet Gynaecol Br Commonw 1969; 76: 684
Guttmacher AF. The incidence of multiple births in man and some other uniparae. Obstet Gynecol 1953; 2: 22
Gorlitsky GA, Kase NG, Speroff L. Ovulation and pregnancy rates with clomiphene citrate. Obstet Gynecol 1978; 51: 265
Gysier M, March CM, Mishell DR, et al. A decades’ experience with an individualized clomiphene treatment regimen including its effects in the postcoital test. Fertil Steril 1982; 37: 161
Fedele L, Brioschi D, Marchini M, et al. Enhanced preovulatory progesterone levels in clomiphene citrate-induced cycles. J Clin Endocrinol Metab 1989; 69: 681–3
Marchini M, Dorta M, Bombelli F, et al. Effects of clomiphene citrate on cervical mucus: analysis of some influencing factors. Int J Fertil 1989; 34: 154–9
Greenblatt RB, Roy S, Mahesh VB, et al. Induction of ovulation. Am J Obstet Gynecol; 1962; 84: 900
Van Hall, EV, Mastboom JL. Luteal phase defect insufficiency in patients treated with clomiphene. Am J Obstet Gynecol 1969; 103: 165
Yuen BH, Mari N, Dulebre AJ, et al. Direct effects of clomiphene citrate of the steroidogenic capability of human granulosa cells. Fertil Steril 1988; 49: 627
Ronnberg L, Kavppila A. Effect of clomiphene citrate on endometrial female sex steroid kinetics. Am J Obstet Gynecol 1988; 159: 272
Fukuma K, Fukushima T, Matsuo I, et al. A graduated regimen of clomiphene citrate: its correlation to glycogen content of the endometrium and serum levels of estradiol and progesterone in infertile patients at the midluteal phase. Fertil Steril 1983; 39: 780
Birkenfeld A, Navot D, Levij IS, et al. Advanced secretory changes in the proliferative human endometrial epithelium following clomiphene citrate treatment. Fertil Steril 1986; 45: 462
Fedele L, Marchini M, Baglioni A, et al. Structural and ultra-structural pattern of the human preovulatory endometrium following clomiphene citrate treatment. Acta Obstet Gynecol Scand 1988; 67: 631–7
Thatcher SS, Donachie KM, Glasier A, et al. The effects of clomiphene citrate on the histology of human endometrium in regularly cycling women undergoing in vitro fertilization. Fertil Steril; 1988; 49: 296–301
Schulz K-D, Holzel F, Bettendorg G. The intracellular distribution of [14C] clomid MRL-14 in various organs of the immature female guinea pig. Hoppe Seylers Z Physiol Chem 1968; 349: 15
Sterzik K, Dallenbach C, Schneider V, et al. In vitro fertilization: the degree of endometrial insufficiency varies with the type of ovarian stimulation. Fertil Steril 1988; 50: 457
Mikaye A, Yoshimoto Y, Hirota K, et al. Effect of clomiphene citrate administration during the early luteal phase on the luteal function and pregnancy rate in women. Euro J Obstet Gynecol Reprod Biol 1987; 26: 19–25
Katz E. The luteinized unruptured follicle and other ovulatory dysfunctions. Fertil Steril 1988; 50: 839–50
Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331: 771–6
Morris JM. Postcoital anti-infertility agents and their teratogenic effects. Contraception 1970; 2: 85
Clark JH, McCormack SA. Clomid or nafoxidine administered to neonatal rats causes reproductive tract abnormalities. Science 1977; 197: 164
Clark JH, McCormack SA. The effect of clomid and other triphenylethylene derivatives during pregnancy and the neonatal period. J Steroid Biochem 1980; 12: 47
McCormack S, Clark JH. Clomid administration to pregnant rats causes abnormalities of the reproductive tract in offspring and mothers. Science 1979; 204: 629
Courtney KD, Valeria DA. Teratology in Macacca mulatta. Teratology 1968; 1: 1633
Cunha GR, Taguchi O, Manikawa R, et al. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbesterol in the developing human genital tract. Hum Pathol 1987; 18: 1132–43
Yoshimura Y, Hosoi Y, Atlas SJ, et al. Effect of the exposure of intrafollicular oocytes to clomiphene citrate on pregnancy outcome in the rabbit. Fertil Steril 1988; 50: 153–8
Yoshimura Y, Hosoi Y, Atlas SJ, et al. Estradiol reverses the limiting effects of clomiphene citrate on early embryonic development in the in vitro perfused rabbit ovary. Fertil Steril 1987; 48: 1030–5
Mor-Joseph S, Anteby SO, Granat M, et al. Recurrent molar pregnancy associated with clomiphene citrate and human gonadotropins. Am J Obstet Gynecol 1985; 151: 1085
Roland M. Problems of ovulation induction with clomiphene citrate with report of a case of ovarian hyperstimulation. Obstet Gynecol 1970; 35: 55
Scommegna A, Lash SR. Ovarian hyperstimulation, massive ascites and singleton pregnancy after clomiphene. JAMA 1969; 207: 753
Rojanasakul A. Massive ascites following induction of ovulation with clomiphene citrate: a case report. J Med Assoc Thai 1988; 71: 86
Southam AL, Janovski NA. Massive ovarian hyperstimulation with clomiphene citrate. JAMA 1962; 181: 443
Muller EE, Cocchi D, Panerai AE, et al. Pituitary hormones and ergot alkaloids. Pharmacol 1978; 1: 63–77
Hokfelt T, Fuxe K. Effects of prolactin and ergot alkaloids on the tuberoinfundibular dopamine neurons. Neuroendocrinol-ogy 1972; 9: 100–22
Lloyd HM, Jacobi JM, Meares JD. DNA sythesis and depletion on DNA synthesis growth and hormone secretion of spontaneous pituitary tumors in the rat. J Endocrinol 1981; 88: 463–9
Katz E, Weiss BE, Schran HF, et al. Increased circulating levels of bromocriptine following vaginal as compared to oral administration. Fertil Steril 1991; 55: 882–4
DelPozo E, Schluter K, Nuesch E, et al. Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effects on release of prolactin and growth hormone. Eur J Clin Pharmacol 1986; 29: 615–8
Katz E, Adashi EY. Bromocriptine for hyperprolactnemic disorders. Contemp Obstet Gynecol 1992; 37: 39–57
DeVane GW. Prolactin inhibitors. In: Rivlin ME, editor. Handbook of drug therapy in reproductive endocrinology and infertility. Boston: Little, Brown & Company, 1990: 110–20
Bigazzi M, Ronga R, Lancranjan I, et al. A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal fetal, and amniotic fluid compartments. J Clin Endocrinol Metab; 1979; 48: 912
Weil C. The safety of bromocriptine in long term use. Curr Med Res Opin 1986; 10: 25–51
Raymond JP, Goldstein E, Konopka P, et al. Follow-up of children born of bromocriptine-treated mothers. Horm Res 1985; 22: 239–46
Lunenfeld B, Sulimovici S, Rabau E, et al. The induction of ovulation in hypophyseal amenorrheics by a combined treatment of urinary menopausal gonadotropins and chorionic gonadotropins. CR Soc Fr Gynecol 1962; 5: 287
Society for Assisted Reproductive Technology. Assisted reproductive technology in the United States and Canada: 1991 results from the Society for Assisted Reproductive Technology generated fom the American Fertility Society registry. Fertil Steril 1993; 59: 956–62
Adashi EY. Managing the ovulatory state: medical induction of ovulation. ACOG Technical Bull 1994; 197 September
Devroey P, Ubaldi F, Smitz J, et al. Recombinant follicle stimulating hormone. Assisted Reprod Rev 1994; 4: 2–9
Navot D, Relau A, Birkenfeld A, et al. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988; 159: 210–5
Navot D, Goldstein N, Mor-Josef, et al. Multiple pregnancies: risk factors and prognostic variables during induction of ovulation with human menopausal gonadotropins. Hum Reprod 1991; 6: 1152–5
Whittemore AS, Harris R, Intyre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136: 1184–203
Spirtas R, Kaufman SC, Alexander NJ. Fertility drugs and ovarian cancer: red alert or red herring? Fertil Steril 1993; 59: 291–3
Caro JJ, Johannes CB, Hartz SC, et al. Re: characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1993; 137: 928
Cohen J, Forman R, Harlap S, et al. IFFS expert group report on the Whittemore study related to the risk of ovarian cancer associated with the use of infertility agents. Hum Reprod 1993; 8: 996–9
Jacobs HS, Adams J, Franks S, et al. Induction of ovulation with luteinizing hormone-releasing hormone: problems, indications and contraindications. J Steroid Biochem 1984; 20: A36
Leyendecker G, Wildt L. Induction of ovulation with chronic intermittent (pulsatile) administration of GnRH in women with hypothalamic amenorrhoea. J Reprod Fertil 1983; 69: 397–409
Scoccia B, Scommegna A. Gonadotropins and gonadotropin releasing factors. In: Rivlin ME, editor. Handbook of drug therapy in reproductive endocrinology and infertility. Boston: Little, Brown & Company, 1990: 75–109
Rosen GF, Yee B. Inducing ovulation with gonadotropin releasing hormone (GnRH) and GnRH agonists. Infertil Reprod Med Clin NA 1990; 1: 121–33
Author information
Authors and Affiliations
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/BF03257466.
Rights and permissions
About this article
Cite this article
Derman, S.G., Adashi, E.Y. Adverse Effects of Fertility Drugs. Drug-Safety 11, 408–421 (1994). https://doi.org/10.2165/00002018-199411060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199411060-00003